Research Papers and Book Chapters
Oct 2023
Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model.
Seda Author(s) H.B. Mistry
Date: Oct 2023
Published: Journal of Pharmacokinetics and Pharmacodynamics
Oct 2023
Radius additivity score: a novel combination index for tumour growth inhibition in fixed-dose xenograft studies
Seda Author(s) N. Melillo, J. Dickinson, H. B. Mistry
Date: Oct 2023
Published: Frontiers in Oncology
Apr 2023
In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate
Seda Author(s) C. Patterson
Date: Apr 2023
Published: International Journal of Pharmaceutics
Mar 2023
Precise and systematic end group chemistry modifications on PAMAM and poly(l-lysine) dendrimers to improve cytosolic delivery of mRNA
Seda Author(s) F. Joubert
Date: Mar 2023
Published: Journal of Controlled Release
Nov 2022
The Global Characterisation of a Drug-Dendrimer Conjugate – PEGylated poly-lysine Dendrimer
Seda Author(s) C. Patterson
Date: Nov 2022
Published: Journal of Pharmaceutical Sciences
September 2022
Determining bioequivalence possibilities of long acting injectables through population PK modelling
Seda Author(s) J. Dickinson, H. Dickinson, L. Ruston, H.B. Mistry, C. Patterson, P.A. Dickinson
Date: September 2022
Published: European Journal of Pharmaceutical Sciences
May 2022
Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series
Seda Author(s) P.A. Dickinson
Date: May 2022
Published: Pharmaceutics
Feb 2022
Developing Cannabinoid Science in the UK: Moving from the Security to the Health Domain
Seda Author(s) P.A. Dickinson
Date: Feb 2022
Published: Decalogue / The Centre for Medicinal Cannabis
Jan 2022
Biopharmaceutics: From Fundamentals to Industrial Practice
Seda Author(s) P.A. Dickinson, L. Ruston, S. Budhdeo, W. W. Lee, C. Patterson
Date: Jan 2022
Published: Wiley, Edited by Hannah Batchelor
Jan 2021
Exploring a model-based analysis of patient derived xenograft studies in oncology drug development
Seda Author(s) J. Dickinson, M. de Matas, P.A. Dickinson, H. Mistry
Date: Jan 2021
Published: PeerJ
Jan 2021
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy
Seda Author(s) C. Patterson
Date: Jan 2021
Published: Communications Biology
Dec 2020
Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge
Seda Author(s) C. Patterson
Date: Dec 2020
Published: Advanced Drug Delivery Reviews
November 2020
Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report
Seda Author(s) P.A. Dickinson
Date: November 2020
Published: Journal of Pharmaceutical Sciences
Nov 2020
IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies
Seda Author(s) C. Patterson, S. Budhdeo
Date: Nov 2020
Published: European Journal of Pharmaceutics and Biopharmaceutics
Jul 2020
Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products
Seda Author(s) P.A. Dickinson
Date: Jul 2020
Published: The AAPS Journal
May 2020
Novel application of synchrotron x-ray computed tomography for ex-vivo imaging of subcutaneously injected polymeric microsphere suspension formulations
Seda Author(s) C. Patterson
Date: May 2020
Published: Pharmaceutical Research
Dec 2018
Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin
Seda Author(s) P.A. Dickinson
Date: Dec 2018
Published: British Journal of Clinical Pharmacology
Jun 2018
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib
Seda Author(s) P.A. Dickinson
Date: Jun 2018
Published: British Journal of Clinical Pharmacology
May 2018
Nonclinical safety and pharmacokinetics of Miglyol 812: A medium chain triglyceride in exenatide once weekly suspension
Seda Author(s) C. Patterson
Date: May 2018
Published: Journal of Applied Toxicology
Apr 2018
The effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non-small cell lung cancer and in healthy volunteers
Seda Author(s) P.A. Dickinson
Date: Apr 2018
Published: Journal of Clinical Pharmacology
Sep 2017
Emerging trends in therapeutic algorithm of chronic wound healers: Recent advances in drug delivery systems, concepts-to-clinical application, and future prospects
Seda Author(s) M. de Matas
Date: Sep 2017
Published: Critical Reviews™ in Therapeutic Drug Carrier Systems
Mar 2017
The impact of formulation attributes and process parameters on black seed oil loaded liposomes and their performance in animal models of analgesia
Seda Author(s) M. de Matas
Date: Mar 2017
Published: Saudi Pharmaceutical Journal
Nov 2016
Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid
Seda Author(s) P.A. Dickinson
Date: Nov 2016
Published: Journal of Pharmaceutical Sciences
Sep 2016
Clinical pharmacology profile of an oral selective androgen receptor down-regulator, AZD3514: Implications on the design of ongoing castrate-resistant prostate cancer clinical studies
Seda Author(s) P.A. Dickinson
Date: Sep 2016
Published: Cancer Research Frontiers
Sep 2016
Asymmetric Distribution in Twin Screw Granulation
Seda Author(s) M. de Matas
Date: Sep 2016
Published: European Journal of Pharmaceutics and Biopharmaceutics
Aug 2016
Metabolic disposition of osimertinib in rat, dog, and man: insights into a drug designed to bind covalently to a cysteine residue of EGFR
Seda Author(s) P.A. Dickinson
Date: Aug 2016
Published: Drug Metabolism and Disposition
Jul 2016
Strategic framework for education and training in quality by design (QbD) and process analytical technology (PAT)
Seda Author(s) M. de Matas
Date: Jul 2016
Published: European Journal of Pharmaceutical Sciences
May 2016
Systems pharmacology modeling of prostate-specific antigen in prostate cancer patients treated with an androgen receptor antagonist and down-regulator
Seda Author(s) P.A. Dickinson
Date: May 2016
Published: CPT Pharmacometrics and Systems Pharmacology
Apr 2016
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies
Seda Author(s) P.A. Dickinson
Date: Apr 2016
Published: Cancer Chemotherapy and Pharmacology
Jan 2016
Clinically Relevant Dissolution for Low-Solubility Immediate-Release Products
Seda Author(s) P.A. Dickinson, P. Stott
Date: Jan 2016
Published: Poorly Soluble Drugs: Dissolution and Drug Release.
Posters and Abstracts
June 2024
Investigating the influence of manufacturing process of lipid-based formulations on intracellular delivery of siRNA
Seda Author(s) F. Joubert, C. Patterson
Date: June 2024
Published: ETPN 2024 / Milam
December 2023
Model Informed-Development of Amorphous Systems (MI-DAS) – an in-silico polymer selection tool for ASD development
Seda Author(s) E. Roberts, S. Rahman, S. Ahmed, H. Dickinson, P. Gajjar, T. Austin, S. Budhdeo, M. de Matas, P. Stott
Date: December 2023
Published: British Journal of Pharmacy
Oct 2022
Setting up success in the clinic through semi-mechanistic translational modelling
Seda Author(s) J. Dickinson
Date: Oct 2022
Published: AAPS PharmSci 360, Boston
July 2022
Population PK modelling as an alternative route to bioequivalence
Seda Author(s) J. Dickinson, H. Dickinson, L. Ruston. H.B. Mistry, C. Patterson, P.A. Dickinson
Date: July 2022
Published: British Journal of Pharmacy
April 2022
Development of a methodology to enable non-linear in vitro-in vivo correlation for complex long-acting injections
Seda Author(s) J. Dickinson, C. Patterson, P.A. Dickinson
Date: April 2022
Published: Quantitative Systems Pharmacology Conference 2022
September 2021
First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies
Seda Author(s) P.A. Dickinson
Date: September 2021
Published: OncologyPRO
September 2021
Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)
Seda Author(s) P.A. Dickinson
Date: September 2021
Published: OncologyPRO
September 2021
Evaluation of In-situ UV Fibre Optic Arch Probe vs. traditional offline LC-UV analysis for ‘real-world’ dissolution studies
Seda Author(s) S-N. Teoh, H. Dickinson, P.A. Dickinson, C. Patterson
Date: September 2021
Published: Virtual APS PharmSci 2021
September 2021
Development of a methodology to enable non-linear in vitro-in vivo correlation for complex long-acting injections
Seda Author(s) J. Dickinson, C. Patterson, P. Gajjar, P.A. Dickinson
Date: September 2021
Published: AAPS PharmSci 360
Nov 2018
Analysis of patient derived xenograft studies in Oncology drug development: impact on design and interpretation of future studies
Seda Author(s) J. Dickinson, M. de Matas, P.A. Dickinson
Date: Nov 2018
Published: PKUK, Midland Hotel, Manchester, UK
Other
Nov 2024